Lynx Biosciences Closes Seed Equity Funding

Lynx Biosciences, Inc., a San Diego, CA-based biotechnology company, closed its Series Seed Preferred Stock offering.

The amount of the funding was not disclosed.

The round was led by Checkmate Capital Group, with participation from Great Oaks Venture Capital, and existing investors, including WARF Ventures and Cove Fund.

Led by founder and CEO Chorom Pak, LynxBio is a commercial-stage biotechnology company combining patient-derived suspension cell co-culture assays, multi-omic readouts, and deep learning analytics to rapidly advance drug candidates in oncology and bring personalized cancer treatments to patients. The company’s MicroC3™ platform is able to characterize complex diseases and therapies where suspension cells play critical roles, including hematological cancers, immunotherapies, and cell-based therapies.

The proceeds will allow the company to continue the development of its MicroC3 platform to address unmet needs in oncological treatment and research.

To date, Lynk has entered into collaborations with a number of community hospitals, NCI-designated cancer centers, and top-ten biopharmaceutical companies who have used the platform to advance promising drug candidates and identify predictive biomarkers in clinical studies.